Tags

Type your tag names separated by a space and hit enter

First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Hematol Oncol Clin North Am. 2018 Oct; 32(5):853-864.HO

Abstract

Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this review.

Authors+Show Affiliations

Immunology Program, Memorial Sloan Kettering Cancer Center, 408 East 69th Street, New York, NY 10021, USA.Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: Palombam@mskcc.org.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30190023

Citation

Argyropoulos, Kimon V., and M Lia Palomba. "First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia." Hematology/oncology Clinics of North America, vol. 32, no. 5, 2018, pp. 853-864.
Argyropoulos KV, Palomba ML. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018;32(5):853-864.
Argyropoulos, K. V., & Palomba, M. L. (2018). First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Hematology/oncology Clinics of North America, 32(5), 853-864. https://doi.org/10.1016/j.hoc.2018.05.012
Argyropoulos KV, Palomba ML. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018;32(5):853-864. PubMed PMID: 30190023.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. AU - Argyropoulos,Kimon V, AU - Palomba,M Lia, Y1 - 2018/07/19/ PY - 2018/9/8/entrez PY - 2018/9/8/pubmed PY - 2019/3/1/medline KW - BTK KW - Ibrutinib KW - Second-generation BTK inhibitors KW - Waldenström macroglobulinemia SP - 853 EP - 864 JF - Hematology/oncology clinics of North America JO - Hematol. Oncol. Clin. North Am. VL - 32 IS - 5 N2 - Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Updates on ibrutinib and second-generation BTK inhibitors are summarized in this review. SN - 1558-1977 UR - https://www.unboundmedicine.com/medline/citation/30190023/First_Generation_and_Second_Generation_Bruton_Tyrosine_Kinase_Inhibitors_in_Waldenström_Macroglobulinemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0889-8588(18)30738-X DB - PRIME DP - Unbound Medicine ER -